Accolade, Inc.

NasdaqGS:ACCD Stock Report

Mkt Cap: US$866.7m

Accolade Past Performance

Past criteria checks 0/6

Accolade's earnings have been declining at an average annual rate of -54.8%, while the Healthcare industry saw earnings growing at 11.9% annually. Revenues have been growing at an average rate of 31.7% per year.

Key information

-54.8%

Earnings growth rate

33.7%

EPS growth rate

Healthcare Industry Growth11.9%
Revenue growth rate31.7%
Return on equity-97.0%
Net Margin-126.6%
Last Earnings Update28 Feb 2023

Recent past performance updates

Recent updates

Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?

May 02
Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?

An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued

Feb 05
An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued

Accolade: Inching Closer To Profitability

Oct 17

Accolade Q2 2023 Earnings Preview

Oct 05

Accolade: Fair And Reasonably Priced, But Needs More Time

Aug 09

Accolade Q1 2023 Earnings Preview

Jun 29

Accolade: Little Recent Applause

Mar 28

Accolade Impresses With Revenue Growth But Faces Operating Losses

Dec 16

Accolade: I May Add To My Position

Oct 18

Accolade, Inc. (NASDAQ:ACCD) Just Reported And Analysts Have Been Lifting Their Price Targets

Jul 11
Accolade, Inc. (NASDAQ:ACCD) Just Reported And Analysts Have Been Lifting Their Price Targets

Accolade, Inc. 2021 Q4 - Results - Earnings Call Presentation

May 06

Here's Why We're Not Too Worried About Accolade's (NASDAQ:ACCD) Cash Burn Situation

Mar 19
Here's Why We're Not Too Worried About Accolade's (NASDAQ:ACCD) Cash Burn Situation

Is Accolade, Inc. (NASDAQ:ACCD) Popular Amongst Institutions?

Jan 15
Is Accolade, Inc. (NASDAQ:ACCD) Popular Amongst Institutions?

Accolade is up 7% on acquisition of 2nd.MD

Jan 14

Accolade Inc.: Bullish Outlook As Its HealthTech Platform Helps Companies Save

Jan 12

Accolade, Inc. 2021 Q3 - Results - Earnings Call Presentation

Jan 11

Accolade Q3 2021 Earnings Preview

Jan 06

Earnings and Revenue History

Quality Earnings: ACCD is currently unprofitable.

Growing Profit Margin: ACCD is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ACCD is unprofitable, and losses have increased over the past 5 years at a rate of 54.8% per year.

Accelerating Growth: Unable to compare ACCD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACCD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-9.8%).

Return on Equity

High ROE: ACCD has a negative Return on Equity (-97.02%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies